Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis

Liliana López, Martha Robayo, Margarita Vargas, Iván D Vélez, Liliana López, Martha Robayo, Margarita Vargas, Iván D Vélez

Abstract

Background: Pentavalent antimonials (Sb5) and miltefosine are the first-line drugs for treating cutaneous leishmaniasis in Colombia; however, toxicity and treatment duration negatively impact compliance and cost, justifying an active search for better therapeutic options. We compared the efficacy and safety of thermotherapy and meglumine antimoniate for the treatment of cutaneous leishmaniasis in Colombia.

Method: An open randomized Phase III clinical trial was performed in five military health centres. located in northwestern, central and southern Colombia. Volunteers with parasitological positive diagnosis (Giemsa-stained smears) of cutaneous leishmaniasis were included. A single thermotherapy session involving the application of 50°C at the center and active edge of each lesion. Meglumine antimoniate was administered intramuscularly at a dose of 20 mg Sb5/kg weight/day for 20 days.

Results: Both groups were comparable. The efficacy of thermotherapy was 64% (86/134 patients) by protocol and 58% (86/149) by intention-to-treat. For the meglumine antimoniate group, efficacy by protocol was 85% (103/121 patients) and 72% (103/143) by intention-to-treat, The efficacy between the treatments was statistically significant (p 0.01 and < 0.001) for analysis by intention to treat and by protocol, respectively. There was no difference between the therapeutic response with either treatment regardless of the Leishmania species responsible for infection. The side effects of meglumine antimoniate included myalgia, arthralgia, headache and fever. Regarding thermotherapy, the only side effect was pain at the lesion area four days after the initiation of treatment.

Conclusion: Although the efficacy rate of meglumine antimoniate was greater than that of thermotherapy for the treatment of cutaneous leishmaniasis, the side effects were also greater. Those factors, added to the increased costs, the treatment adherence problems and the progressive lack of therapeutic response, make us consider thermotherapy as a first line treatment for cutaneous leishmaniasis.

Trial registration: ClinicalTrials.gov NCT00471705.

References

    1. Bailey MS, Lockwood DN. 2. Cutaneous leishmaniasis. Clin Dermatol. 2007;25:203–211. doi: 10.1016/j.clindermatol.2006.05.008. Mar-Apr.
    1. Bejarano EE, Sierra D, Perez-Doria A, Velez ID. First finding of Lutzomyia tihuiliensis (Diptera: Psychodidae) in the Valle de Aburra, Colombia. Biomedica. 2006;26(Suppl 1):228–231.
    1. WHO (World Health Organization).Control of the leishmaniases. 2010.
    1. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2009;2:CD004834.
    1. Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos-Cuentas A. et al.Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis. 2007;44(12):1549–1554. doi: 10.1086/518172.
    1. Berman JD. Treatment of New World cutaneous and mucosal leishmaniases. Clin Dermatol. 1996;14(5):519–522. doi: 10.1016/0738-081X(96)00048-X. Sep-Oct.
    1. Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, Kedzierska K. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem. 2009;16(5):599–614. doi: 10.2174/092986709787458489.
    1. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005;366(9496):1561–1577. doi: 10.1016/S0140-6736(05)67629-5. Oct 29-Nov 4.
    1. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat. 2004;7(4–5):257–266. Aug-Oct.
    1. Palumbo E. Current treatment for cutaneous leishmaniasis: a review. Am J Ther. 2009;16(2):178–182. doi: 10.1097/MJT.0b013e3181822e90. Mar-Apr.
    1. Sampaio RN, de Paula CD, Sampaio JH, Furtado Rde S, Leal PP, Rosa TT. et al.The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis. Rev Soc Bras Med Trop. 1997;30(6):457–463. doi: 10.1590/S0037-86821997000600003. Nov-Dec.
    1. Seaton RA, Morrison J, Man I, Watson J, Nathwani D. Out-patient parenteral antimicrobial therapy–a viable option for the management of cutaneous leishmaniasis. QJM. 1999;92(11):659–667. doi: 10.1093/qjmed/92.11.659.
    1. Soto J, Soto P. Current situation and future of antileishmanial therapy in Colombia. Biomedica. 2006;26(Suppl 1):194–206.
    1. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006;3(5):e162. doi: 10.1371/journal.pmed.0030162.
    1. Hadighi R, Boucher P, Khamesipour A, Meamar AR, Roy G, Ouellette M. et al.Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res. 2007;101(5):1319–1322. doi: 10.1007/s00436-007-0638-0.
    1. Osorio LE, Palacios R, Chica ME, Ochoa MT. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet. 1998;351(9101):498–499.
    1. Momeni AZ, Aminjavaheri M, Omidghaemi MR. Treatment of cutaneous leishmaniasis with ketoconazole cream. J Dermatolog Treat. 2003;14(1):26–29. doi: 10.1080/09546630305552.
    1. Singh S, Singh R, Sundar S. Failure of ketoconazole treatment in cutaneous leishmaniasis. Int J Dermatol. 1995 Feb;34(2):120–121. doi: 10.1111/j.1365-4362.1995.tb03595.x.
    1. Hendrickx EP, Agudelo SP, Munoz DL, Puerta JA, Velez Bernal ID. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am J Trop Med Hyg. 1998 Dec;59(6):889–892.
    1. Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F. et al.Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med. 2010;126(3):232–236.
    1. Soto J, Berman J. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg. 2006 Dec;100(Suppl 1):S34–S40.
    1. Soto J, Toledo JT. Oral miltefosine to treat new world cutaneous leishmaniasis. Lancet Infect Dis. 2007 Jan;7(1):7.
    1. Velez I, Lopez L, Sanchez X, Mestra L, Rojas C, Rodriguez E. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg. 2010;83(2):351–6. doi: 10.4269/ajtmh.2010.10-0060.
    1. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A. et al.Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop. 2007 Jul;103(1):33–40. doi: 10.1016/j.actatropica.2007.05.005.
    1. Esmaeili J, Mohebali M, Edrissian GH, Rezayat SM, Ghazi-Khansari M. et al.Evaluation of miltefosine against Leishmania major (MRHO/IR/75/ER): in vitro and in vivo studies. Acta Med Iran. 2008;46(3):191–196.
    1. Bari AU, Rahman SB. A Therapeutic update on Cutaneous leishmaniasis. J Coll Physicians Surg Pak. 2003 Aug;13(8):471–476.
    1. Willard RJ, Jeffcoat AM, Benson PM, Walsh DS. Cutaneous leishmaniasis in soldiers from Fort Campbell, Kentucky returning from Operation Iraqi Freedom highlights diagnostic and therapeutic options. J Am Acad Dermatol. 2005 Jun;52(6):977–987. doi: 10.1016/j.jaad.2005.01.109.
    1. Levine N. Cutaneous leishmaniasis treated with controlled localized heating. Arch Dermatol. 1992 Jun;128(6):759–761. doi: 10.1001/archderm.1992.01680160041003.
    1. Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg. 1990 Jan;42(1):43–50.
    1. Velasco-Castrejon O, Walton BC, Rivas-Sanchez B, Garcia MF, Lazaro GJ, Hobart O. et al.Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico. Am J Trop Med Hyg. 1997 Sep;57(3):309–312.
    1. Moreira Rda C, Rebelo JM, Gama ME, Costa JM. Knowledge level about of American tegumentary leishmaniasis (ATL) and use of alternative therapies in an endemic area in the Amazon Region in the State of Maranhao, Brazil. Cad Saude Publica. 2002;18(1):187–195. doi: 10.1590/S0102-311X2002000100019. Jan-Feb.
    1. Velez ID, Hendrickx E, Robledo SM, del Pilar Agudelo S. Gender and cutaneous leishmaniasis in Colombia. Cad Saude Publica. 2001;17(1):171–180. doi: 10.1590/S0102-311X2001000100018. Jan-Feb.
    1. Weigel MM, Armijos RX. The traditional and conventional medical treatment of cutaneous leishmaniasis in rural Ecuador. Rev Panam Salud Publica. 2001;10(6):395–404. doi: 10.1590/S1020-49892001001200005.
    1. Adams E. Thermosurgery in dermatology. Boston, MA: Thecnology Assessment Program, Office of Patient Care Services. 2008.
    1. Ramirez JR, Agudelo S, Muskus C, Alzate JF, Berberich C, Barker D. et al.Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitologic diagnosis. J Clin Microbiol. 2000;38(10):3768–3773.
    1. Robinson RJ, Agudelo S, Muskus C, Alzate JF, Berberich C, Barker DC. et al.The method used to sample ulcers influences the diagnosis of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 2002;96(Suppl 1):S169–S171.
    1. Montalvo Alvarez AM, Nodarse JF, Goodridge IM, Fidalgo LM, Marin M, Van Der Auwera G. et al.Differentiation of Leishmania (Viannia) panamensis and Leishmania (V.) guyanensis using BccI for hsp70 PCR-RFLP. Trans R Soc Trop Med Hyg. 2010;104(5):364–7. doi: 10.1016/j.trstmh.2009.12.002.
    1. Montalvo AM, Monzote L, Fraga J, Montano I, Muskus C, Marin M. et al.PCR-RFLP and RAPD for typing neotropical Leishmania. Biomedica. 2008;28(4):597–606.
    1. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V. et al.CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003 Jul;13(3):176–181. doi: 10.1016/S1053-4296(03)00031-6.
    1. Guía de atención de la leishmaniasis. Ministerio de la Proteccion Social, Bogotá; 2007.
    1. Soto JTJ, Vega J, Berman J. Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis. Am J Trop Med Hyg. 2005;72(4):421–422. Apr.
    1. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg. 2001;64(3–4):187–193.
    1. Vélez IDA, del Pilar Agudelo S, Hendrickx E, Puerta JA, Grogl M, Modabber F. et al.Inefficacy of allopurinol as monotherapy for colombian cutaneus leishmaniasis. Ann Intern Med. 1997;126:232–236.
    1. Reithinger RMM, Wahid M, Bismullah M, Quinnell RJ, Davies CR. et al.Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis. 2005;40(8):1148–1155. doi: 10.1086/428736. Apr 15.
    1. Aronson NE, Wortmann GW, Byrne WR, Howard RS, Bernstein WB, Marovich MA. et al.A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis. 2010;4(3):628. doi: 10.1371/journal.pntd.0000628.
    1. Tuon FF, Amato VS, Graf ME, Siqueira AM, Nicodemo AC, Amato Neto V. Treatment of New World cutaneous leishmaniasis–a systematic review with a meta-analysis. Int J Dermatol. 2008 Feb;47(2):109–124. doi: 10.1111/j.1365-4632.2008.03417.x.
    1. Vega JC, Sanchez BF, Montero LM, Montana R, Mahecha Mdel P, Duenes B. et al.The efficacy of thermotherapy to treat cutaneous leishmaniasis in Colombia: a comparative observational study in an operational setting. Trans R Soc Trop Med Hyg. 2009 Jul;103(7):703–706. doi: 10.1016/j.trstmh.2008.10.039.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner